Vaximm AG, an OSR Company, Enters Term Sheet With BCM Europe for Potential VXM01 License with $20M Upfront and Up to $815M in Milestones

Core Viewpoint - Vaximm AG, a subsidiary of OSR Holdings, has entered a non-binding term sheet with BCM Europe AG to explore a potential exclusive global licensing agreement for its oral cancer immunotherapy platform, VXM01, which is a significant step towards accelerating its development and commercialization [1][3]. Group 1: Licensing Agreement Details - The term sheet establishes a six-month exclusivity period for negotiating a definitive licensing agreement, subject to due diligence and Board approvals [2][4]. - BCME is positioned as a strategic financial intermediary, funding the necessary partnering and development activities to secure a global out-license with a major pharmaceutical company [2]. - The proposed structure includes an optional blockchain-based royalty participation mechanism using "TAC" tokens to represent future royalty revenue streams [3]. Group 2: Financial Aspects - Vaximm is set to receive a $20 million upfront payment, with potential milestone payments totaling up to $815 million, along with a pass-through of commercial royalties from any future pharmaceutical partner [8]. Group 3: Company Background - OSR Holdings, Inc. is a global healthcare holding company focused on advancing biomedical innovations in healthcare and wellness, engaging in immuno-oncology, regenerative biologics, and medical device technologies [5]. - Vaximm AG is a Swiss-German biotechnology company specializing in oral T-cell vaccination platforms, with its lead candidate VXM01 targeting VEGFR-2 and showing clinical activity in multiple cancer indications [6].